{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:07:36Z","timestamp":1789592856336,"version":"build-2803163510"},"reference-count":17,"publisher":"European Respiratory Society (ERS)","issue":"1","funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2017,11,20]]},"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and predefined sputum bacteria.<\/jats:p>\n                  <jats:p>Patients were randomised 2:1 to twice-daily ciprofloxacin DPI 32.5\u2005mg or placebo in 14- or 28-day on\/off treatment cycles for 48\u2005weeks. Primary end-points were time to first exacerbation and frequency of exacerbations. Enrolling countries and \u03b1 level split (0.049 and 0.001 for 14- and 28-day cycles, respectively) differed from RESPIRE 1.<\/jats:p>\n                  <jats:p>\n                    Patients were randomised to ciprofloxacin DPI (14\u2005days on\/off (n=176) or 28\u2005days on\/off (n=171)) or placebo (14\u2005days on\/off (n=88) or 28\u2005days on\/off (n=86)). The exacerbation rate was low across treatment arms (mean\u00b1\n                    <jats:sc>sd<\/jats:sc>\n                    0.6\u00b10.9). Active treatment showed trends to prolonged time to first exacerbation (ciprofloxacin DPI 14\u2005days on\/off: hazard ratio 0.87, 95.1% CI 0.62\u20131.21; p=0.3965; ciprofloxacin DPI 28\u2005days on\/off: hazard ratio 0.71, 99.9% CI 0.39\u20131.27; p=0.0511) and reduced frequency of exacerbations (ciprofloxacin DPI 14\u2005days on\/off: incidence rate ratio 0.83, 95.1% CI 0.59\u20131.17; p=0.2862; ciprofloxacin DPI 28\u2005days on\/off: incidence rate ratio 0.55, 99.9% CI 0.30\u20131.02; p=0.0014), although neither achieved statistical significance. Ciprofloxacin DPI was well tolerated.\n                  <\/jats:p>\n                  <jats:p>Trends towards clinical benefit were seen with ciprofloxacin DPI, but primary end-points were not met.<\/jats:p>","DOI":"10.1183\/13993003.02053-2017","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T20:10:16Z","timestamp":1516911016000},"page":"1702053","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":180,"title":["RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis"],"prefix":"10.1183","volume":"51","author":[{"given":"Timothy","family":"Aksamit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-0344","authenticated-orcid":false,"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiemo-Joerg","family":"Bandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Criollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Operschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"2024101909261072000_51.1.1702053.1","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.007516"},{"key":"2024101909261072000_51.1.1702053.2","first-page":"6","article-title":"Inflammation: a two-edged sword \u2013 the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur J Respir Dis Suppl"},{"key":"2024101909261072000_51.1.1702053.3","doi-asserted-by":"publisher","DOI":"10.1183\/18106838.0604.342"},{"key":"2024101909261072000_51.1.1702053.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00119114"},{"key":"2024101909261072000_51.1.1702053.5","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-015-0167-9"},{"key":"2024101909261072000_51.1.1702053.6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11136-012-0188-5","article-title":"Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life","volume":"22","author":"Olveira","year":"2013","journal-title":"Qual Life Res"},{"key":"2024101909261072000_51.1.1702053.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201309-1575OC"},{"key":"2024101909261072000_51.1.1702053.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02052-2017"},{"key":"2024101909261072000_51.1.1702053.9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cct.2017.05.007","article-title":"The RESPIRE trials: two phase III, randomised, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis","volume":"58","author":"Aksamit","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"2024101909261072000_51.1.1702053.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01899-2015"},{"key":"2024101909261072000_51.1.1702053.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00051-2017"},{"key":"2024101909261072000_51.1.1702053.12","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00170014"},{"key":"2024101909261072000_51.1.1702053.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00026313"},{"key":"2024101909261072000_51.1.1702053.14","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.118778"},{"key":"2024101909261072000_51.1.1702053.15","doi-asserted-by":"publisher","DOI":"10.1157\/13128330"},{"key":"2024101909261072000_51.1.1702053.16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5694\/mja14.00287","article-title":"Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand: Thoracic Society of Australia and New Zealand guidelines","volume":"202","author":"Chang","year":"2015","journal-title":"Med J Aust"},{"key":"2024101909261072000_51.1.1702053.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02053-2017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:49:46Z","timestamp":1740361786000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02053-2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,25]]},"published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1183\/13993003.02053-2017"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02053-2017","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732571638.793557656","asserted-by":"object"}]},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}